{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:30:39Z","timestamp":1790069439913,"version":"4.0.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/background:<\/jats:title>\n                    <jats:p>Hepatic veno-occlusive disease (VOD) is well recognized potentially serious regimen-related toxicity seen after stem cell transplantation. Severe VOD is associated with poor long-term outcomes with very high mortality. Besides supportive care, only defi-brotide has been found to be effective in the management of VOD. The recommended dose of defibrotide is 25 mg\/kg\/d but there has been no classical dose finding study done for this drug. A higher dose of defibrotide is associated with increased risk of bleeding and this drug is prohibitively expensive. We report our experience of using fixed low dose of defibrotide in patients with VOD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively evaluated 511 patients who underwent stem cell transplant at our center from November 2007 and December 2015. All patients received ursodeoxycholic acid as VOD prophylaxis. Modified Seattle criterion was used for diagnosis and severity grading of VOD. Patients developing VOD were initially treated with furosemide and adequate analgesia. Defibrotide was started within 12 to 24 hours of diagnosis of VOD. All adult patients received defibrotide at a fixed dose of 200 mg twice daily while two children were given dose of 100 mg and 50 mg twice daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Nine (1.7%) of our patients developed VOD. Daily dose of defibrotide ranged from 5 mg\/kg\/d to 20 mg\/kg\/d till resolution of VOD. All patients had complete resolution of VOD. None of our patients required ventilator support or dialysis. No episodes of bleeding were observed. No dose response relationship was observed between defibrotide dose and time to resolution of VOD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Low fixed dose defibrotide initiated early seems to be effective and safe in treatment of VOD. This is relevant in a resource limited setting and warrants prospective evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.02.005","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T15:02:35Z","timestamp":1493132555000},"page":"47-51","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation"],"prefix":"10.4103","volume":"11","author":[{"given":"Bhausaheb","family":"Bagal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Chandrasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Chougle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2017.02.005_b0005","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.hemonc.2017.02.005_b0010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.hemonc.2017.02.005_b0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hemonc.2017.02.005_b0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.02.005_b0025","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.005_b0030","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.02.005_b0035","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.bbmt.2015.08.013","article-title":"Escalation to high-dose defibrotide in patients with hepatic veno-occlusive disease","volume":"21","author":"Triplett","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.02.005_b0040","doi-asserted-by":"crossref","first-page":"A518","DOI":"10.1016\/j.jval.2015.09.1578","article-title":"Defibrotide in veno-occlusive disease in public hospitals of paris: funding issues and perspectives","volume":"18","author":"Steelandt","year":"2015","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.hemonc.2017.02.005_b0045","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.bbmt.2015.11.378","article-title":"Early initiation of defibrotide in patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome following hematopoietic stem cell transplantation improves day +100 survival","volume":"22","author":"Richardson","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.hemonc.2017.02.005_b0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","article-title":"Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention","volume":"33","author":"Corbacioglu","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.02.005_b0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.005_b0060","article-title":"Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation","author":"Gupta","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hemonc.2017.02.005_b0065","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.bbmt.2009.12.532","article-title":"Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Ramos","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.02.005_b0070","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"The Lancet"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201811010-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:48:55Z","timestamp":1787838535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201811010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.02.005","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}